Biotechnology company Maze Therapeutics submitted an IPO application for the US stock market, aiming to raise $100 million
Biotechnology company Maze Therapeutics has submitted an IPO application to the U.S. Securities and Exchange Commission, planning to raise $100 million. The company focuses on developing precision small molecule therapies for kidney diseases and other indications, with clinical trials expected to begin in the first quarter of 2025. Maze Therapeutics was founded in 2017 and plans to list on NASDAQ under the ticker symbol MAZE
According to the Zhitong Finance APP, biotechnology company Maze Therapeutics submitted an IPO application to the U.S. Securities and Exchange Commission on Tuesday, planning to raise $100 million.
Maze Therapeutics is a Phase II biotechnology company developing precision small molecule therapies for kidney diseases and other indications.
Maze Therapeutics is developing novel small molecule precision drugs for patients with kidney, cardiovascular, and related metabolic diseases (including obesity). The company is advancing a product line using its Compass platform, which enables it to identify and characterize genetic variations in diseases and then link these variations to biological pathways that cause diseases in specific patient populations. Its leading candidate, MZE829, is an oral small molecule apolipoprotein L1 (APOL1) inhibitor for treating patients with APOL1-mediated kidney disease.
Maze reported Phase I trial results for MZE829 in October 2024, showing that the treatment has good tolerability, and it initiated Phase II trials in November 2024. The company expects to administer the first patient injection in the first quarter of 2025 and obtain proof-of-concept data in the first quarter of 2026.
Founded in 2017, the company reported licensing revenue of $168 million for the 12 months ending September 30, 2024. The company plans to list on NASDAQ under the ticker symbol MAZE.
Maze Therapeutics submitted a confidential application on June 21, 2024. JP Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the joint bookrunners for the transaction. The company did not disclose pricing terms